* Need to vaccinate earlier for seasonal flu
* Eighth death reported in U.S.
* New H1N1 strain still affecting younger people more
By Maggie Fox, Health and Science Editor
WASHINGTON, May 20 (Reuters) - U.S. health officials said on Wednesday they are considering starting the vaccination campaign for seasonal flu earlier this year to make room for a possible second round of shots against the new H1N1 flu.
The United States also reported its eighth death from the new swine flu virus, in a patient in Arizona.
"If possible we do want to have an earlier rollout of seasonal vaccine," Dr Daniel Jernigan of the U.S. Centers for Disease Control and Prevention told reporters in a telephone briefing.
He said the CDC would work with manufacturers of influenza vaccines and a committee of doctors that advises on vaccination policy to see if that would be possible and desirable. Flu vaccination usually starts in September in the United States and peaks in November.
Vaccine experts agree it would be better to launch a second round of vaccinations against the new H1N1 strain instead of trying to add it to the seasonal flu vaccine or replacing one of its three components with the new H1N1 virus.
"The production of seasonal flu vaccine is nearly complete," Jernigan said.
On Wednesday, the CDC reported 5,710 confirmed and probable cases of the new H1N1 strain in 48 states, with eight deaths. Globally, more than 10,000 cases have been confirmed with 80 deaths, most in Mexico.
Jernigan said it is clearly still affecting younger people more in the United States — 40 percent of the 247 people who have been hospitalized with serious illness from the new H1N1 strain are aged 19 to 49, he said.
Seasonal influenza puts 200,000 Americans in the hospital every year and is a factor in 36,000 deaths, but 90 percent are over 65 or have chronic diseases such as asthma and heart disease that make them more vulnerable. With the new H1N1 flu, Jernigan said, 70 percent of hospitalized patients have an underlying condition.
AGE 50 ADVANTAGE
Only 13 percent of people who have been hospitalized with swine flu are over 50, Jernigan said, and he said tests of blood among the general population may eventually show whether people born before 1957 may have been infected with an older H1N1 strain that was close to the swine flu strain. They may then have some lifetime resistance to the new strain, he said.
In 1957, a new flu strain called H2N2 caused a pandemic and became the predominant strain of flu circulating globally. There is a seasonal H1N1 strain that still circulates but it is only a very distant relative of the new swine flu strain.
Seasonal flu is also still infecting people but Jernigan said 78 percent of U.S. cases tested for influenza are the new H1N1 strain. The CDC and state health departments are only doing targeted testing and say the true number of flu cases across the country is likely more than 100,000.
Jernigan said many flu patients are getting antibiotics — which prevent so-called secondary infections — but not enough are getting the antiviral drugs Tamiflu and Relenza, which are known to help symptoms.
Tamiflu, or oseltamivir, is made by Roche AG ROG.VX and Gilead Sciences Inc (GILD.O) while the inhaled drug Relenza, or zanamivir, is made by GlaxoSmithKline (GSK.N) and Biota Inc BTA.AX.
The new flu seems to be about as contagious as seasonal flu, Jernigan said.
He was unable to say why so many more people are infected in the United States than in countries such as Britain, which reports 102 cases, but said there may have been more U.S. travelers to Mexico and more time for the virus to spread.
(Editing by Eric Beech)